Understanding the neurophysiology of reinforcement and craving will improve our ability to develop new medications for the treatment of substance abuse. We have developed procedures for, and have ongoing behavioral studies of, acute cocaine administration and controlled withdrawal which quantify cardiovascular and subjective effects, mood and craving. While there are one or two centers where imaging is carried out following a single cocaine dose, none, to our knowledge, have ever imaged the effects of repeated doses followed by abstinence. Our ability to perform functional imaging on subjects where the administration and withdrawal from cocaine is controlled by the experimenter is an important advantage. We are proposing a five-year study to correlate cocaine's subjective effects with its effects on regional brain activity using dynamic Xenon SPECT, a high-resolution, full-volume, 3-D imaging system which permits quantification of cerebral blood flow at multiple timepoints in a single experiment. Current efforts at medication development are hampered by the lack of markers that would provide early indications of possible effectiveness. We believe that rCBF imaging using high-resolution 133Xenon-SPECT can be developed in carefully designed studies as a marker for drug effects and will ultimately improve treatment outcome. By analyzing time course of pattern changes in brain activity we will shed light on the determinants of cocaine-induced euphoria, reinforcement, dysphoria, and craving. Our center is particularly suited to do this.
Specific Aims : 1) Define the initial temporal profile of cerebral activation in acute cocaine administration and a) correlate this profile with subjective experience in a dose-responsive manner using standard subjective effects measures and other observational data; b) confirm that the effect of acute tolerance is to attenuate this activation. 2) Define physiologic markers for the stages of withdrawal and so develop targets for treatment intervention. 3) Demonstrate cerebral activation by cues which elicit craving and a) correlate this activation with self-administration behavior; b) examine the effect of expectation on cue response and the corresponding cerebral activation. Use of these tools, and the data derived from their use, can be of major importance in Medication Development research. They could lead to pharmacological interventions in the treatment of cocaine abuse which could: Prevent cerebral activation by a drug of abuse by modulating receptors; Normalize neurotransmitter activity in the withdrawal state; Diminish relapse likelihood by attenuating the cerebral activation produced by craving.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA009236-04
Application #
6237977
Study Section
Project Start
1997-09-30
Project End
1998-08-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
4
Fiscal Year
1997
Total Cost
Indirect Cost
Name
New York State Psychiatric Institute
Department
Type
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Brezing, Christina A; Choi, C Jean; Pavlicova, Martina et al. (2018) Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment-seekers with cannabis use disorder. Am J Addict 27:101-107
Cooper, Ziva D; Bedi, Gillinder; Ramesh, Divya et al. (2018) Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. Neuropsychopharmacology 43:2046-2055
Chao, Thomas; Radoncic, Vanya; Hien, Denise et al. (2018) Stress responding in cannabis smokers as a function of trauma exposure, sex, and relapse in the human laboratory. Drug Alcohol Depend 185:23-32
Babalonis, Shanna; Haney, Margaret; Malcolm, Robert J et al. (2017) Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend 172:9-13
Metz, Verena E; Sullivan, Maria A; Jones, Jermaine D et al. (2017) Racial Differences in HIV and HCV Risk Behaviors, Transmission, and Prevention Knowledge among Non-Treatment-Seeking Individuals with Opioid Use Disorder. J Psychoactive Drugs 49:59-68
Metz, Verena E; Jones, Jermaine D; Manubay, Jeanne et al. (2017) Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence. Neuropsychopharmacology 42:1825-1832
Vadhan, Nehal P; Corcoran, Cheryl M; Bedi, Gill et al. (2017) Acute effects of smoked marijuana in marijuana smokers at clinical high-risk for psychosis: A preliminary study. Psychiatry Res 257:372-374
Bachtell, Ryan K; Jones, Jermaine D; Heinzerling, Keith G et al. (2017) Glial and neuroinflammatory targets for treating substance use disorders. Drug Alcohol Depend 180:156-170
Cooper, Ziva D; Johnson, Kirk W; Pavlicova, Martina et al. (2016) The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers. Addict Biol 21:895-903
Herrmann, Evan S; Cooper, Ziva D; Bedi, Gillinder et al. (2016) Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users. Psychopharmacology (Berl) 233:2469-78

Showing the most recent 10 out of 129 publications